<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="0" ids="25354">mineralocorticoid</z:chebi> receptor (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) <z:chebi fb="68" ids="48706">antagonists</z:chebi> have protective effects in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, but the cell type-specific actions of these drugs are unknown </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we examined the contribution of myeloid cell <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> during focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> using myeloid-specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> knockout mice </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: myeloid-specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> knockout mice were subjected to transient (90 minutes) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 24 hours reperfusion (n=5 to 7 per group) </plain></SENT>
<SENT sid="3" pm="."><plain>Ischemic cerebral <z:mpath ids='MPATH_124'>infarcts</z:mpath> were identified by <z:chebi fb="1" ids="51686">hematoxylin</z:chebi> and eosin staining and quantified with image analysis software </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemical localization of microglia and macrophages was performed using Iba1 staining, and the expression of inflammatory markers was measured after 24 hours of reperfusion by quantitative reverse transcription-polymerase chain reaction </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: myeloid-specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> knockout resulted in a 65% reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (P=0.005) after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>This was accompanied by a significant reduction in activated microglia and macrophages in the ischemic core </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, myeloid-specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> knockout suppressed classically activated M1 macrophage markers <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-α, interleukin-1β, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, and interleukin-6 at the same time as partially preserving the induction of alternatively activated, M2, markers Arg1, and Ym1 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: these data demonstrate that myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> activation exacerbates <z:hpo ids='HP_0001297'>stroke</z:hpo> and identify myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> as a critical target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, these data indicate that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> activation has an important role in controlling immune cell function during the <z:mp ids='MP_0001845'>inflammatory response</z:mp> to <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>